- 14 March
-
At the end of the last year, Novouralsk-based Medsintez Plant turned 20 years old. Alexander Petrov, Chairman of the plant's Board of Directors, told Regions of Russia about the impressive successes that the company has achieved over the years and its ambitious plans for the future.
- 22 January
-
In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease. The preparations are available in the most convenient and familiar for patients dosage form – a disposable prefilled injection and have already been supplied to pharmacies.
- 13 December
-
Medsintez Plant LLC presented the latest biotechnological developments of pharmaceuticals at the largest international scientific and practical forum in the field of medicine and health care Russian Health Care Week — 2023 held from December 4 to December 8 in Moscow. The main purpose of the Forum is to facilitate the implementation of the national projects “Healthcare” and “Demography”, “Tourism and Hospitality Industry”, the federal project “Development of Medical Services Export”, as well as summarizing the results of the Year of Science and Technology in Medicine.
- 04 October
-
On September 27, as part of the business program of the GMP conference with international participation, Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant LLC, took part in a Plenary Session on the issues of regulating the circulation of medicines in Russia and the EAEU, developing import independence, and increasing export potential. The session was attended by representatives of the Ministry of Industry and Trade of the Russian Federation, the Minister of Health of the Republic of Nicaragua, the WHO Representative in Russia, a Representative of the Serbian Ministry of Health and other Russian and foreign experts. Mr. Petrov spoke about the problems that Russian pharmaceutical companies face when entering international markets and suggested possible solutions.
- Home
- Cluster members
- Ural Biomedical Company LLC
Ural Biomedical Company LLC
Genetic and gene and cell technologies (GCT), which make it possible to modify the properties of cells in a targeted manner, is a direction that the UN has officially recognized as a technology of the 21st century.
Hopes for the treatment of the most severe and massive diseases, such as cardiovascular, oncological and metabolic diseases, are associated with success in the development of GCT.
The small innovative enterprise Ural Biomedical Company LLC acts as a coordinator in this area, bringing together the efforts of specialists from the Department of Molecular and Cellular Technologies of the Ural State Medical University and the Laboratory of Cell and Gene Therapy Technology of the Institute of Medical Cellular Technologies in conducting an R&D cycle and implementing innovative projects for the development, production and use of a new generation of personalized medicines based on gene and gene-cell technologies based on the patented developments of one of the leading scientific schools in Russia – Professor O. G. Makeev's School.
Currently, the studies coordinated by Ural Biomedical Company LLC are at different stages of preclinical and clinical trials, which are highly recognized both in Russia and abroad – in particular, representatives of the above scientific school have obtained dozens of patents, have been awarded gold medals at European and Russian forums and exhibitions of biomedical technologies.
According to the National Society of Regenerative Medicine, a unique product for the Russian and world markets – AversGel – a gel for natural skin rejuvenation based on components of a certified human stem cell line, entered the top 10 breakthrough technologies in Russia in 2017 with the comment: "These technologies will remain with us for a long time. They will change the economy and politics, make a breakthrough in medicine, leave a cultural mark. Some of them are just taking shape, while others can take more than a decade to develop. But you need to know about them right now.”
